Suppr超能文献

普伐他汀治疗预防犬胰岛自体移植的原发性无功能

Prevention of primary nonfunction of canine islet autografts by treatment with pravastatin.

作者信息

Arita Seiji, Nagai Tetsu, Ochiai Mari, Sakamoto Yoshimasa, Shevlin Linda A, Smith Craig V, Mullen Yoko

机构信息

Islet Transplant Program, Department of Surgery, UCLA School of Medicine and Veterans Affairs Medical Center/West Los Angeles, California 90073, USA.

出版信息

Transplantation. 2002 Jan 15;73(1):7-12. doi: 10.1097/00007890-200201150-00003.

Abstract

BACKGROUND

Nonspecific inflammation is the primary cause of early islet graft loss. We have shown in mice that pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, prevents primary nonfunction of islet isografts by reducing inflammatory reactions at the graft site. This study was designed to test the effectiveness of this agent in a large animal model, dogs, by transplanting autologous islets.

METHODS

After total pancreatectomy, islets were isolated by using a two-step digestion method, followed by discontinuous gradient centrifugation on EuroFicoll. A known number of freshly isolated islets were immediately transplanted back into the same dog via the portal vein.

RESULTS

First, we determined the minimal islet number required to reverse diabetes by transplanting 3,000-10,000 IEQ/kg with no additional treatment. The number was found to be 4,000 IEQ/kg, and islets less than 4,000 IEQ/kg consistently failed. To test the effect of pravastatin, 3,000 IEQ/kg were transplanted into dogs that either received no further treatment or were treated daily with 20 mg/kg of pravastatin from days -2 to 14. Without pravastatin, this number of islets lowered blood glucose only transiently, and all four of these dogs became hyperglycemic within 1 week. In contrast, four of the five dogs treated with pravastatin became normoglycemic (<150 mg/dL) and maintained this level during the observation period of 12 weeks (P<0.05). Postprandial plasma glucose and insulin levels returned to normal, and K values of intravenous glucose tolerance tests were significantly higher in pravastatin-treated dogs than in controls (P<0.04 at week 2 and P<0.01 at week 4).

CONCLUSION

Peritransplant pravastatin treatment reduced the number of autologous islets required to reverse diabetes in totally pancreatectomized dogs. These results suggest that pravastatin may also facilitate better islet graft survival and function in clinical transplantation.

摘要

背景

非特异性炎症是早期胰岛移植失败的主要原因。我们在小鼠中已表明,3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂普伐他汀可通过减少移植部位的炎症反应来预防胰岛同基因移植的原发性无功能。本研究旨在通过移植自体胰岛,在大型动物模型犬中测试该药物的有效性。

方法

全胰切除术后,采用两步消化法分离胰岛,随后在欧洲菲可(EuroFicoll)上进行不连续梯度离心。将已知数量的新鲜分离的胰岛立即通过门静脉回输到同一只犬体内。

结果

首先,在不进行额外治疗的情况下,通过移植3000 - 10000 IEQ/kg胰岛来确定逆转糖尿病所需的最小胰岛数量。结果发现该数量为4000 IEQ/kg,低于4000 IEQ/kg的胰岛始终失败。为测试普伐他汀的效果,将3000 IEQ/kg胰岛移植到犬体内,这些犬要么不再接受进一步治疗,要么从第 - 2天至第14天每天接受20 mg/kg普伐他汀治疗。在没有普伐他汀的情况下,这个数量的胰岛仅能使血糖短暂降低,所有这四只犬在1周内均出现高血糖。相比之下,接受普伐他汀治疗的五只犬中有四只血糖恢复正常(<150 mg/dL),并在12周的观察期内维持该水平(P<0.05)。餐后血浆葡萄糖和胰岛素水平恢复正常,普伐他汀治疗的犬静脉葡萄糖耐量试验的K值在第2周时显著高于对照组(P<0.04),在第4周时差异极显著(P<0.01)。

结论

移植前后使用普伐他汀治疗可减少全胰切除犬逆转糖尿病所需的自体胰岛数量。这些结果表明,普伐他汀在临床移植中可能也有助于提高胰岛移植的存活率和功能。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验